On March 15, 2023 Veracyte, Inc. (Nasdaq: VCYT) reported that three abstracts highlighting the company’s unique, multi-omics capabilities and offerings for biopharmaceutical partners will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida (Press release, Veracyte, MAR 15, 2023, View Source [SID1234628801]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Veracyte’s comprehensive multi-omics expertise and tools provide our biopharma partners with actionable insights to help them confidently advance every step of their oncology drug development programs," said Corinne Danan, general manager of Veracyte’s Biopharma business unit. "The abstracts accepted for presentation at AACR (Free AACR Whitepaper) 2023 will highlight new learnings and tools that demonstrate our ongoing commitment to continually enhancing and expanding the services available to these partners."
Following are details of the Veracyte abstracts that will be shared during poster sessions at the AACR (Free AACR Whitepaper) Annual Meeting 2023:
Title:
Deciphering the tumor microenvironment at single-cell resolution using a workflow combining RNA transcript and protein detection with Brightplex, a sequential chromogenic multiplex assay
Presenter:
Jacques Fieschi, Ph.D., Veracyte
Date/Time:
Tuesday, April 18, 1:30-5:00 p.m. ET
Location:
Poster Section 4
Poster #:
14
Abstract #:
4624
Title:
Veracyte Biopharma Atlas for colorectal cancer: combining multi-parameter approach and machine learning to capture the complexity of the tumor immune contexture.
Presenter:
Florence Monville, Ph.D., Research Discovery, Veracyte
Date/Time:
Tuesday, April 18, 1:30-5:00 p.m. ET
Location:
Poster Section 37
Poster #:
26
Abstract #:
5476
Title:
Defining the cancer Immunogram using multimodal analysis to guide immunotherapy in diffuse large B cell lymphoma
Presenter:
Régis Perbost, Ph.D., Veracyte and Mike Mattie, Ph.D., Kite a Gilead company
Date/Time:
Wednesday, April 19, 9:00 a.m.-12:30 p.m. ET
Location:
Poster Section 4
Poster #:
21
Abstract #:
5879
Veracyte will also host a Spotlight Theater at AACR (Free AACR Whitepaper) 2023, highlighting how insights from the company’s multi-omics offerings and analytical capabilities can help biopharma partners more confidently advance oncology drug development programs
Title:
Leveraging multi-omics insights to advance drug development programs
Speakers:
Corinne Danan, General Manager, Biopharma Services, Veracyte
Jacques Fieschi, Ph.D., Research Discovery, Veracyte
Jérôme Galon, Ph.D., Scientific Executive Director, Veracyte, and Research Director, Inserm
Date/Time:
Sunday, April 16, 3:30-4:30 p.m. ET
Location:
Exhibit Hall, Spotlight Theater